Skip to main content

Scars

1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Tissue Repair
Tissue RepairAustralia - Sydney
1 program
1
CACIPLIQ20®Phase 31 trial
Active Trials
NCT05528328Unknown50Est. Oct 2024
Cytrellis Biosystems
1 program
MCDN/A1 trial
Active Trials
NCT03782038Recruiting30Est. Nov 2019
Ache Laboratorios Farmaceuticos
1 program
Silicon-based productsN/A1 trial
Active Trials
NCT02584010Withdrawn0Est. Oct 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Tissue RepairCACIPLIQ20®
Cytrellis BiosystemsMCD
Ache Laboratorios FarmaceuticosSilicon-based products

Clinical Trials (3)

Total enrollment: 80 patients across 3 trials

Post-surgical Scars After the Use of CACIPLIQ20

Start: Mar 2023Est. completion: Oct 202450 patients
Phase 3Unknown

Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars

Start: Sep 2018Est. completion: Nov 201930 patients
N/ARecruiting

Efficacy Study of Two Silicon-based Products to Treat Scars

Start: Jan 2016Est. completion: Oct 20160
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 80 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.